Analysis of Influencing Factors on Clinical Outcomes and Evaluation of Corticosteroid Efficacy in Patients with Severe Influenza

Every year, seasonal influenza sweeps through communities, a familiar respiratory illness that most people shake off within a week. For the vast majority, the body's natural defenses are enough to clear the virus. However, for a smaller group of people—particularly the elderly, those with chronic health conditions, or individuals with weakened immune systems—the infection can spiral into a severe, life-threatening condition. When the virus triggers a massive, uncontrolled inflammatory response, it can damage the lungs and other organs, leading to respiratory failure and death. In these critical moments, doctors face a difficult dilemma: how to calm the body's destructive overreaction without disabling its ability to fight the virus itself. One common tool in the medical arsenal for taming inflammation is corticosteroids, powerful drugs that suppress the immune system. While these medications are standard for many conditions, their use in severe flu remains a subject of intense debate. Some evidence suggests they might help by reducing lung swelling, while other studies warn they could hinder the body's fight against the virus or invite new infections.

To cut through this uncertainty, a team of researchers at The First Affiliated Hospital of Shihezi University in China looked back at the medical records of 343 patients who had been hospitalized with severe influenza between 2017 and 2025. Their goal was twofold: first, to identify which specific factors made a patient more likely to have a poor outcome just one week after diagnosis, and second, to see if giving corticosteroids actually helped, and if the amount of the drug mattered. They focused on a seven-day window because it captures the early, critical phase of the illness before other complications, like hospital-acquired infections, could muddy the results. By examining data ranging from patient age and initial illness severity to specific blood test results, the team sought to find patterns that could guide future treatment decisions.

The researchers found that three specific factors stood out as independent predictors of a patient's fate within that first week. The first was age; older patients faced a higher risk of a poor outcome. The second was the severity of the illness when the patient first arrived at the hospital; those who were already in critical condition were far more likely to struggle. The third factor was a specific enzyme found in the blood called aspartate aminotransferase, or AST. When this enzyme is elevated, it signals that the virus or the body's immune response is causing damage to the liver, heart, or muscles. Patients with higher levels of this enzyme at the start of their hospital stay were more likely to have a difficult recovery. These findings suggest that doctors can use age, how sick a patient looks upon arrival, and this specific blood marker to quickly identify who needs the most aggressive support.

When the team turned their attention to corticosteroids, the picture became more nuanced. Overall, the study did not find a blanket benefit for giving these drugs to every patient with severe flu. In fact, when looking at the entire group, the use of corticosteroids did not significantly change the rate of survival or recovery at the seven-day mark. However, the story changed when the researchers looked closer at specific subgroups. They discovered that for elderly patients, the use of corticosteroids appeared to level the playing field. In patients who did not receive the drugs, age was a strong predictor of a bad outcome; in those who did receive the drugs, age no longer seemed to matter as much. This suggests that the medication might help older patients overcome the specific vulnerabilities that usually make them more susceptible to severe complications. Similarly, the drug seemed to offer a potential benefit for patients with high levels of the AST enzyme, hinting that it might help mitigate the organ damage associated with those elevated levels.

The researchers also investigated whether the dose of the corticosteroid made a difference. They compared patients who received high doses against those who received low-to-medium doses. While the study did not reach a level of statistical certainty to declare one dose definitively superior, the data showed a clear trend. Patients treated with lower to moderate doses appeared to have better outcomes than those given high doses. High doses might be too aggressive, potentially suppressing the immune system so much that it delays the clearing of the virus or opens the door to other infections. In contrast, a moderate amount might be enough to calm the dangerous inflammation without completely shutting down the body's defenses.

It is important to note that these findings come from a single hospital and rely on looking back at past records, which means the results are suggestive rather than final proof. The researchers acknowledge that larger, forward-looking studies are needed to confirm these patterns and to determine the exact right dose for the right patient. Nevertheless, this work provides a clearer map for understanding severe influenza. It confirms that age, initial severity, and specific blood markers are key indicators of risk. It also suggests that while corticosteroids are not a universal cure, they may offer a targeted lifeline for the most vulnerable patients, particularly the elderly, when used in measured, moderate amounts rather than high, overwhelming doses.